
Fine-grained List-wise Alignment for Generative Medication Recommendation

Chenxiao Fan¹ Chongming Gao^{1*} Wentao Shi¹
Yaxin Gong¹ Zihao Zhao¹ Fuli Feng^{1*}

¹University of Science and Technology of China

{simonfan, shiwentao123, gyx2022, zzh1998}@mail.ustc.edu.cn
chongminggao@ustc.edu.cn, fulifeng93@gmail.com

Abstract

Accurate and safe medication recommendations are critical for effective clinical decision-making, especially in multimorbidity cases. However, existing systems rely on point-wise prediction paradigms that overlook synergistic drug effects and potential adverse drug-drug interactions (DDIs). We propose FLAME, a fine-grained list-wise alignment framework for large language models (LLMs), enabling *drug-by-drug generation* of drug lists. FLAME formulates recommendation as a sequential decision process, where each step adds or removes a single drug. To provide fine-grained learning signals, we devise step-wise Group Relative Policy Optimization (GRPO) with potential-based reward shaping, which explicitly models DDIs and optimizes the contribution of each drug to the overall prescription. Furthermore, FLAME enhances patient modeling by integrating structured clinical knowledge and collaborative information into the representation space of LLMs. Experiments on benchmark datasets demonstrate that FLAME achieves state-of-the-art performance, delivering superior accuracy, controllable safety-accuracy trade-offs, and strong generalization across diverse clinical scenarios. Our code is available at <https://github.com/cxfann/Flame>.

1 Introduction

Accurate and safe medication recommendation is essential for clinical decision-making, especially in complex cases involving multimorbidity [1, 2]. In these scenarios, clinicians must consider not only the therapeutic effects of individual drugs, but also their potential interactions and cumulative safety risks. Recent advances in AI have led to the development of automated medication recommendation systems [3, 4, 5], yet their effectiveness remains limited in practice.

Traditional approaches typically adopt a point-wise prediction paradigm, where each drug is evaluated independently based on structured patient data such as diagnoses, procedures, and drug codes [6, 7]. While longitudinal models [8] attempt to capture patient history, they are still constrained by their reliance on discrete labels and lack the capacity to represent unstructured clinical context. More recently, large language models (LLMs) have emerged as a promising solution, due to their strong language understanding and ability to incorporate free-text information such as clinical notes [9, 10]. However, most LLM-based methods still follow the point-wise formulation, constructing the final drug set by aggregating drugs with high predicted scores.

This formulation introduces a fundamental limitation: it overlooks the *synergistic effects and safety constraints* that exist between drugs. In practice, effective prescriptions must balance therapeutic efficacy with the risk of adverse drug-drug interactions (DDIs) [11]. Point-wise models, by design,

*Corresponding author




Figure 1: Contrasting advantage computation in GRPO and step-wise GRPO. (a) Outcome-based advantages in GRPO assign a uniform reward to all drugs in a completion. (b) Step-wise GRPO treats the generation as a sequence of medication decisions, where each m_i denotes a distinct drug and simultaneously defines one decision step. Each step is endowed with a potential function, whose change reflects the incremental quality of adding that drug (“Evaluate each step”), and these potential-based signals are aggregated with the list-level outcome reward to yield the final step-wise advantages, enabling finer-grained credit assignment.

cannot account for this interplay. To address this, we argue that medication recommendation should be viewed as a **list-wise decision-making problem**, where the goal is to generate a coherent set of drugs that jointly optimize accuracy and safety.

Existing list-wise methods in NLP often rely on reinforcement learning (RL) techniques to align model outputs with desired properties. One promising approach is Group Relative Policy Optimization (GRPO) [12], which updates model preferences based on relative advantages among a group of candidate outputs. Yet standard GRPO operates at the sequence level (Fig. 1 (a))—assigning a single scalar reward to the entire output—making it difficult to assign credit to individual actions.

To this end, we propose FLAME (**F**ine-grained **L**ist-wise **A**lignment for generative **M**edication **r**ecommendation), an LLM-based framework that formulates drug generation as a *drug-by-drug* decision process. At its core is a novel extension of GRPO—**step-wise GRPO**—which models the generation as a sequence of state transitions. Each step adds or removes a drug, and reward shaping is applied via a potential function to provide token-level feedback (Fig. 1 (b)) throughout the generation process. This structure enables FLAME to learn nuanced and controllable decision policies.

To support comprehensive patient modeling, FLAME incorporates multi-source medical knowledge into the LLM via hybrid representations. In addition to the LLM’s natural language inputs, we inject structured clinical features (e.g., codes, embeddings from prior models) into the token space, enabling the model to capture both textual context and collaborative signals. We build on Llama3.1-AIoe-Beta-8B [13], a domain-specific LLM with enriched medical knowledge.

We evaluate FLAME on benchmark datasets including MIMIC-III [14], MIMIC-IV [15], and eICU [16]. Experimental results show that FLAME achieves state-of-the-art accuracy while maintaining controllable safety trade-offs. Moreover, FLAME exhibits strong generalization across time and institutions, validating its adaptability to real-world clinical scenarios.

Our contributions are summarized as follows:

- We propose FLAME, an LLM-based list-wise medication recommendation framework that generates prescriptions *drug-by-drug*, explicitly modeling drug interactions and integrating multi-source medical knowledge via hybrid representations.
- We introduce step-wise GRPO, which models medication recommendation as a sequential state transition process and leverages potential-based reward shaping to provide fine-grained feedback for each drug-level decision, enabling controllable and clinically safer recommendations.
- Extensive experiments on benchmark datasets demonstrate that FLAME achieves state-of-the-art performance in accuracy, safety–accuracy trade-offs, and cross-dataset generalization, validating its effectiveness in diverse clinical settings.

2 Related Work

In this section, we provide a brief review of medication recommender systems and LLM fine-tuning methods, highlighting their respective strengths and limitations.

2.1 Medication Recommendation

Existing medication recommendation methods can be broadly categorized into *instance-based* and *longitudinal* approaches, based on how patient information is modeled.

Instance-based methods, such as LEAP [6], treat the medication recommendation task as a multi-instance multi-label learning problem. These approaches typically rely on structured features extracted from a single patient visit. In contrast, **longitudinal methods** incorporate temporal information from patients' hospitalization histories to model long-term disease progression and treatment trajectories. For example, GameNet [7] utilizes hospitalization records and a graph augmented memory module to model DDIs. SafeDrug [3] enhances this by using dual molecular graph encoders to capture drug structural information. COGNet [4] introduces a copy-or-predict mechanism for medication recommendation from historical data, while MoleRec [8] focuses on the relationship between health status and molecular substructures. RAREMed [5] uses a pretrain-finetune framework for structured representation extraction, and NLA-MMR [17] applies a multimodal alignment framework to jointly learn from patient and drug views.

Recently, the development of LLMs has brought new possibilities for medication recommendation. Instead of relying solely on structured codes, these approaches leverage natural language to represent patient conditions more comprehensively. For example, LAMO [10] integrates structured diagnoses and procedures with unstructured textual descriptions of patients, enabling LLMs to model clinical context in a semantically rich manner and generate more personalized drug suggestions.

Many existing methods, including recent LLM-based approaches, still follow the point-wise prediction paradigm [18, 19, 20], assigning independent scores or binary labels to individual drugs while ignoring inter-drug dependencies. In contrast, we formulate medication recommendation as a list-wise decision process and introduce step-wise GRPO for fine-grained reward modeling, integrating medical knowledge, collaborative signals, and LLM-based semantic understanding.

2.2 LLM Fine-Tuning Approaches

Fine-tuning LLMs for complex decision tasks has evolved from supervised fine-tuning (SFT) to preference-based reinforcement learning approaches such as reinforcement learning-based fine-tuning (RLHF). While RLHF methods like Proximal Policy Optimization (PPO) [21] offer online adaptability, they incur high overhead due to their multi-component design. Recent advances such as Direct Preference Optimization (DPO) [22] reduce this complexity by leveraging static preference data, but struggle with dynamic optimization.

GRPO [12] further improves training efficiency and policy stability by introducing group-wise relative preference comparisons, achieving strong performance in structured reasoning tasks. However, GRPO remains outcome-based—assigning rewards only to complete outputs—thus failing to capture step-level quality variations within structured decision processes.

Several recent efforts have sought to improve GRPO. DAPO [23] introduces token-level policy-gradient losses to mitigate length bias, ensuring each token contributes equally; however, it still adopts a list-wise advantage formulation, lacking localized reward assignment. StepGRPO [24] decomposes responses into sequential actions and supplements outcome-based evaluation with step-level accuracy and validity rewards. Yet, it continues to aggregate advantages at the list level and often depends on ground-truth process data. While these works enhance signal fidelity and stability, they do not resolve the fine-grained reward allocation problem we address.

On the contrary, step-wise GRPO is a fine-grained alignment method that decomposes generation into decision steps and applies a potential-based reward mechanism to guide each sub-decision. This enables LLMs to better learn the internal logic of complex tasks such as medication recommendation.

3 Preliminary

This section formulates the medication recommendation problem through three components: electronic health record, DDI graph, and the optimization goal. We then introduce Group Relative Policy Optimization, a reinforcement learning framework that models outcome-based advantages.

3.1 Medication Recommendation

Electronic Health Records (EHRs). Each patient's EHR [25] contains both structured and unstructured clinical information and is represented as a sequence of multivariate visits. For a patient j with V historical visits, the EHR is denoted as $\mathbf{X}_V^{(j)} = [\mathbf{x}_1^{(j)}, \mathbf{x}_2^{(j)}, \dots, \mathbf{x}_V^{(j)}]$. Each visit $\mathbf{x}_v^{(j)} \in \mathbf{X}_V^{(j)}$ consists of the following components: $\mathbf{x}_v^{(j)} = [(\mathbf{f}_v^{(j)}, \mathbf{n}_v^{(j)}), \mathcal{M}_v^{(j)}]$, where $\mathbf{f}_v^{(j)} \in \{0, 1\}^{|\mathcal{F}|}$ is a multi-hot vector encoding structured features from the set $\mathcal{F}$ (e.g., demographics, diagnoses, and procedures), and $\mathbf{n}_v^{(j)}$ is the corresponding unstructured clinical note in natural language. The set $\mathcal{M}_v^{(j)}$ denotes the medications prescribed during the v -th visit. For simplicity, we omit the patient index j when it is clear from context.

Drug-Drug Interaction (DDI) Graph. The DDI graph [11] models harmful pairwise interactions between medications and is represented as a symmetric binary adjacency matrix $\mathbf{D} \in \{0, 1\}^{|\mathcal{M}| \times |\mathcal{M}|}$, where $D_{ij} = 1$ indicates a known adverse interaction between medications m_i and m_j .

Task Definition. Given a patient's historical visit records $\mathbf{X}_{V-1}$, as well as the structured fields and unstructured note of the current visit $(\mathbf{f}_V, \mathbf{n}_V)$, the objective is to generate an output $\mathbf{o}_V$, representing the recommended medication set $\mathcal{M}_V$, such that: (1) it closely approximates the ground-truth prescription $\mathcal{M}_{GT}$; and (2) it minimizes the risk of harmful drug-drug interactions as defined by the DDI graph $\mathbf{D}$.

3.2 Group Relative Policy Optimization (GRPO)

GRPO [12] is a reinforcement learning algorithm that improves policies via group-wise reward normalization. Given a prompt $q \sim P(Q)$ from the task distribution, GRPO samples a group of G candidate outputs $\{\mathbf{o}_i\}_{i=1}^G$ from the current policy $\pi_{\theta_{old}}$. Each output is assigned a scalar reward, and the updated policy π_{θ} is optimized to favor relatively better responses within the group.

The training objective (omitting clipping for brevity) is:

$$\mathcal{J}_{GRPO}(\theta) = \mathbb{E}_{q, \{\mathbf{o}_i\}} \left[\frac{1}{G} \sum_{i=1}^G \frac{1}{|\mathbf{o}_i|} \sum_{t=1}^{|\mathbf{o}_i|} \left(\frac{\pi_{\theta}(\mathbf{o}_{i,t} | \mathbf{o}_{i, < t}, q)}{\pi_{\theta_{old}}(\mathbf{o}_{i,t} | \mathbf{o}_{i, < t}, q)} \hat{A}_{i,t} - \beta D_{KL}[\pi_{\theta} \| \pi_{ref}] \right) \right], \quad (1)$$

where β controls the KL divergence regularization toward a reference policy π_{ref} .

The token-level advantage $\hat{A}_{i,t}$ is uniformly derived from the normalized reward of the full response:

$$\hat{A}_{i,t} = \tilde{r}_i = \frac{r_i - \text{mean}(\mathbf{r})}{\text{std}(\mathbf{r})}, \quad (2)$$

where r_i is the scalar reward for the i -th output, $\mathbf{r} = [r_1, \dots, r_G]$ is the reward vector for the group.

Although GRPO effectively promotes group-wise preference learning, its outcome-level reward is applied uniformly across all tokens, ignoring variation in token-level quality. This coarse credit assignment hinders fine-grained learning and limits optimization efficiency.

4 Method: FLAME

We first introduce step-wise GRPO, the core of FLAME's fine-grained alignment. We then describe the optimization process, followed by the two-stage recommendation framework. Finally, we present the multi-source knowledge fusion strategy.

4.1 Step-wise GRPO

Output Segmentation. To enable fine-grained credit assignment, we decompose the LLM output into multiple decision steps [26], each corresponding to a semantically coherent token span (e.g., a single medication). Given a generated sequence $\mathbf{o}_i = [o_i^1, o_i^2, \dots, o_i^{|\mathbf{o}_i|}]$, we segment it into N_i steps:

$$\mathbf{o}_i = \bigcup_{n=1}^{N_i} \mathbf{o}_i^{(n)}, \quad \text{where } \mathbf{o}_i^{(n)} = [o_i^{b_n}, \dots, o_i^{e_n}]. \quad (3)$$




Figure 2: (a) Output is segmented by medication names into decision steps. (b) Each step is viewed as a state, with potentials $\varphi(n)$ derived from comparisons with ground truth $\mathcal{M}_{GT}$. (c) Potential differences are combined with outcome rewards to provide fine-grained training signals $\hat{A}$.

Each $\mathbf{o}_i^{(n)}$ denotes the token span of the n -th step. The process is illustrated in (Fig. 2).

This segmentation allows us to reinterpret generation as a Markov Decision Process, where each step forms a state-action pair. This framing enables localized reward signals that better align step-wise actions with the global output quality.

Potential-based Reward Shaping. We extend the standard GRPO advantage (Eq. 2) with a shaping term that captures quality changes between consecutive steps:

$$\hat{A}_{i,t} = \tilde{r}_i + \lambda \cdot F(\text{step}(t), \text{step}(t) - 1) \quad (4)$$

Here, $\text{step}(t)$ maps token t to its step index, and $F(\cdot, \cdot)$ measures step-wise potential difference. λ is a weighting coefficient. To preserve policy invariance [27], we define F as the difference of a real-valued potential function φ :

$$F(n, n-1) = \gamma \cdot \varphi(n) - \varphi(n-1) \quad (5)$$

with $\gamma = 1$, assuming equal importance across steps.

Final Advantage. The final advantage used for policy optimization becomes:

$$\hat{A}_{i,t} = \tilde{r}_i + \lambda (\varphi(\text{step}(t)) - \varphi(\text{step}(t) - 1)) \quad (6)$$

This formulation delivers dense training signals aligned with intermediate decision quality [28], encouraging token-level improvements toward globally effective prescriptions.

4.2 Fine-grained Alignment for Medication Recommendation

We apply step-wise GRPO to our list-wise medication recommendation task by treating each decision step as a span representing a single medication. We define:

- *State* s_n : the patient profile and current medication set $\mathcal{M}_n$.
- *Action* a_n : adding or removing a medication m_n .

The state transition follows:

$$\mathcal{M}_{n+1} = \begin{cases} \mathcal{M}_n \cup \{m_n\}, & \text{if adding,} \\ \mathcal{M}_n \setminus \{m_n\}, & \text{if removing.} \end{cases} \quad (7)$$

To evaluate the quality of intermediate states, we define a step-level potential function $\varphi(\text{step}(t))$ incorporating: (1) **Correctness**: Jaccard similarity to the ground-truth set $\mathcal{M}_{GT}$, (2) **Adherence**: constraint violation with respect to the candidate set $\mathcal{M}_C$ (all unique medications in the processed training data), and (3) **Safety**: DDI-based risk from the interaction graph $\mathbf{D}$. The potential function is given by:

$$\varphi(\text{step}(t)) = \text{Jaccard}(\mathcal{M}_n, \mathcal{M}_{GT}) - \alpha \cdot \text{DDI}(\mathcal{M}_n, \mathbf{D}) - \beta \cdot \text{RefusalRate}(\mathcal{M}_n, \mathcal{M}_C) \quad (8)$$

where:

$$\begin{aligned} \text{Jaccard}(\mathcal{M}_n, \mathcal{M}_{GT}) &= \frac{|\mathcal{M}_n \cap \mathcal{M}_{GT}|}{|\mathcal{M}_n \cup \mathcal{M}_{GT}|}, & \text{RefusalRate}(\mathcal{M}_n, \mathcal{M}_C) &= \frac{|\{m \in \mathcal{M}_n \mid m \notin \mathcal{M}_C\}|}{|\mathcal{M}_n|}. \\ \text{DDI}(\mathcal{M}_n, \mathbf{D}) &= \frac{|\{(m_i, m_j) \mid m_i, m_j \in \mathcal{M}_n, i < j, \mathbf{D}[m_i, m_j] = 1\}|}{\binom{|\mathcal{M}_n|}{2}}. \end{aligned}$$




Figure 3: Illustration of the two-stage recommendation framework.

This potential function $\varphi(\text{step}(t))$ allows computing local advantage via step-wise differences (Eq. 6), assigning credit based on incremental improvement in the medication set $\mathcal{M}_n$. The overall list-level reward is defined as the net potential change from the initial to the final step:

$$R_i = \varphi(N_i) - \varphi(0) \quad (9)$$

Theorem 4.1 (Optimal Policy Equivalence under Reward Reshaping). *Let the token-level reward for each token t in the generated output $\mathbf{o}_i$ be defined under the following two schemes:*

$$(1) \text{ Outcome-based reward: } r_{i,t} = \begin{cases} R_i, & \text{if } t \text{ is the terminal token,} \\ 0, & \text{otherwise} \end{cases} \quad (10)$$

$$(2) \text{ Step-wise shaped reward: } r'_{i,t} = \varphi(\text{step}(t)) - \varphi(\text{step}(t) - 1) \quad (11)$$

Then, both reward formulations yield the same optimal policy.

The proof is provided in Appendix A.

Using the potential-shaped advantage $\hat{A}_{i,t}$ in Eq. (6), we optimize the policy via step-wise GRPO, while retaining the same objective form as standard GRPO (Eq. (1)).

4.3 Two-stage Recommendation Framework

We adopt a cascaded framework to generate an accurate and safe medication set $\mathcal{M}_v$ for a patient's v -th visit. The process consists of two stages: drug-level filtering and list-level refinement. The former is implemented via a binary classification model, and the latter through a policy fine-tuned with step-wise GRPO, as illustrated in Fig. 3.

Drug-level Classifier (π_{cls}). We implement π_{cls} as an LLM-based binary classifier, obtained by SFT the Llama3.1-Aloe-Beta-8B [13] base model, that evaluates the relevance of each candidate drug $m \in \mathcal{M}_c$ given the patient input x . The model returns a Yes/No decision, producing a personalized subset:

$$\mathcal{M}_p = \{m \in \mathcal{M}_c \mid \pi_{\text{cls}}(x, m) = \text{Yes}\}. \quad (12)$$

This step establishes personalized relevance by filtering drugs based on individual compatibility prior to joint reasoning.

List-wise Policy (π_{list}). To support global optimization, we introduce a list-wise policy π_{list} that performs instruction-conditioned edits over $\mathcal{M}_p$. Given patient input x , a medication list $\mathcal{M}$, and an instruction (Add Drug or Remove Drug), the model predicts a modification set:

$$\Delta\mathcal{M} = \pi_{\text{list}}(x, \mathcal{M}, \text{Instruction}). \quad (13)$$

We initialize π_{list} with π_{cls} , leveraging its drug-patient matching ability, and further adapt it to instruction-driven editing via supervised fine-tuning and step-wise GRPO (see Section 4.1).

Inference. At inference, we first apply π_{cls} to obtain $\mathcal{M}_p$ using Eq. (12), then perform list-level edits:

$$\Delta\mathcal{M}_{\text{add}} = \pi_{\text{list}}(x, \mathcal{M}_p, \text{Add Drug}), \quad \Delta\mathcal{M}_{\text{remove}} = \pi_{\text{list}}(x, \mathcal{M}_p, \text{Remove Drug}). \quad (14)$$

The final recommendation is obtained by applying the edits:

$$\mathcal{M}_v = (\mathcal{M}_p \cup \Delta\mathcal{M}_{\text{add}}) \setminus \Delta\mathcal{M}_{\text{remove}}. \quad (15)$$

This two-stage procedure combines individualized assessment with global reasoning for more controllable and context-aware recommendations. Implementation details, including prompt templates and training setup, are provided in Appendix C.




Figure 4: Overview of patient representation construction.

4.4 Multi-source Knowledge Fusion

Traditional methods often encode structured inputs (e.g., diagnoses, procedures) into embeddings and integrate external knowledge via architectural modules such as graph encoders [3, 7]. However, LLMs operate primarily on unstructured text, making the incorporation of structured signals non-trivial.

We propose a fusion mechanism that injects collaborative signals from structured sources into LLMs [29, 30], as illustrated in Fig. 4. For each structured entity, we construct two complementary representations: a *textual embedding* $\mathbf{e}^{\text{text}} \in \mathbb{R}^d$ from natural language descriptions, and a *collaborative embedding* $\mathbf{e}^{\text{collab}} \in \mathbb{R}^{d'}$ from a domain-specific encoder. The collaborative embedding is projected into the LLM space via a learnable linear map $\mathcal{P} : \mathbb{R}^{d'} \rightarrow \mathbb{R}^d$, yielding:

$$\mathbf{e}^{\text{fused}} = \text{Concat}(\mathbf{e}^{\text{text}}, \mathcal{P}(\mathbf{e}^{\text{collab}})) \quad (16)$$

This fusion enriches LLM inputs with high-level domain signals. We use four types of collaborative embeddings: **(1) Patient-level:** from RAREMed [5], a pretrained model encoding clinical context via a transformer. **(2) Diagnosis-level** and **(3) Procedure-level:** from MICRON [31], capturing co-occurrence patterns from EHRs. **(4) Medication-level:** from Mole-BERT [32], modeling drug substructure–function relationships via molecular graphs.

Moreover, we adopt **Llama3.1-Aloe-Beta-8B** [13], a medical LLM, as our backbone, enabling the fusion of structured embeddings with textual semantics. This hybrid representation not only enhances the model to capture fine-grained clinical signals but also benefits from the comprehensive medical knowledge encoded in the LLM, together forming our multi-source knowledge fusion framework.

5 Experiments

We begin by detailing the experimental setup. We then evaluate FLAME against baselines across three dimensions: accuracy, safety–accuracy trade-offs, and cross-dataset generalization. Finally, an ablation study assesses the contribution of each component in our framework.

5.1 Experimental Settings

Datasets. We use real-world EHR datasets: MIMIC-III [14] for training and evaluation, and MIMIC-IV [15] and eICU [16] for generalization testing. DDI relations are obtained from TWOSIDES [11]. Following prior works, MIMIC-III is split into training/validation/test sets (4:1:1).

Implementation. All methods are implemented in PyTorch and trained on NVIDIA A100 GPUs. Details on preprocessing, hyperparameters, and prompts are in Appendices B and C.

Baselines. We compare FLAME with: (1) Traditional methods: LEAP [6], GAMENet [7], Safe-Drug [3], COGNet [4], MICRON [31], MoleRec [8], NLA-MMR [17], RAREMed [5]; (2) LLM-based method: LAMO [10].

Metrics. Correctness is evaluated by Jaccard similarity and F1 score; safety by DDI rate. Definitions and calculation details are in Appendix C.

5.2 Overall Performance Comparison

We evaluate FLAME from three perspectives: **correctness**, **safety controllability**, and **generalizability**. EHR datasets contain inherent DDI risks (e.g., 13.69% in MIMIC-III), meaning data fitting does not guarantee safe prescriptions. Minimizing DDIs often compromises accuracy, making the correctness–safety trade-off a key metric for practical utility.

Unlike prior works reporting a single performance point, we explicitly decouple correctness and safety in evaluation, enabling a clearer assessment of a model’s reasoning ability and controllability under varying safety constraints. To assess generalization, we further test on MIMIC-IV and eICU, examining performance under distribution shifts beyond the training domain.

Correctness Comparison. Table 1 reports correctness results on MIMIC-III. Instance-based models (e.g., LEAP) perform poorly due to a lack of historical context modeling. Longitudinal models like SafeDrug and GAMENet improve performance by leveraging temporal data, while MoleRec further enhances accuracy by incorporating molecular substructure information. RAREMed achieves stronger results with transformer-based clinical representations. The LLM-based LAMO benefits from unstructured clinical notes but lacks structured co-occurrence knowledge, limiting its potential. Our proposed FLAME outperforms all baselines in Jaccard and F1 scores by formulating medication recommendation as a list-wise decision problem and fusing multi-source clinical knowledge.

Safety Control Comparison. We evaluate controllable safety by adjusting the penalty parameter α in Eq. 8, generating recommendations under varying DDI constraints. Fig. 5(a) shows Jaccard–DDI trade-off curves. Among models supporting safety control, FLAME consistently achieves better accuracy–safety balance than baselines. Notably, methods like LAMO are excluded as they lack safety adjustment mechanisms. These results validate the effectiveness of step-wise GRPO in enabling controllable, clinically safer recommendations.

Generalization Comparison. We assess generalization through temporal and external validations. For temporal validation, models trained on MIMIC-III are evaluated on MIMIC-IV, which covers newer time periods and ICD-10 codes. Fig. 5(b) shows that LLM-based models (FLAME, LAMO) degrade less over time compared to structured-data baselines, highlighting the robustness of language-based representations to coding shifts. FLAME further surpasses LAMO due to its integration of multi-source knowledge and step-wise reasoning.

For external validation, we evaluate on eICU, a multi-center dataset with distributional and coding differences. As shown in Fig. 5(c), LLM-based methods again outperform structured-input baselines. FLAME achieves superior out-of-distribution performance, demonstrating the advantage of combining list-wise decision modeling with collaborative knowledge fusion.

Table 1: Correctness comparison on MIMIC-III. #Med indicates the average number of prescribed medications per patient (ground truth: 23.43).

Model	Jaccard	F1	#Med
LEAP	0.3073	0.4610	19.69
SafeDrug	0.3556	0.5135	22.94
GAMENet	0.3851	0.5422	20.02
COGNet	0.3876	0.5458	28.45
MICRON	0.3843	0.5419	20.49
NLA-MMR	0.3867	0.5453	25.54
MoleRec	0.4081	0.5677	24.73
RAREMed	0.4174	0.5776	23.03
LAMO	0.4701	0.6294	23.66
FLAME	0.4836	0.6408	22.24




Figure 5: Comparison with strong baselines. (a) Safety–accuracy trade-off on MIMIC-III. (b) Temporal generalization from MIMIC-III to MIMIC-IV. (c) External generalization to eICU.

Table 2: Ablation study. “w/o” denotes “without”.

Model Variants	Jaccard	F1
(a) w/o π_{cls}	0.3473	0.5024
(b) w/o π_{list}	0.4785	0.6354
(c) w/o SFT in π_{list}	0.4810	0.6382
(d) w/o step-wise GRPO in π_{list}	0.4789	0.6367
(e) with standard GRPO	0.4813	0.6385
(f) w/o structured codes	0.4535	0.6122
(g) w/o unstructured notes	0.4104	0.5692
(h) w/o $\mathbf{e}^{\text{text}}$	0.3930	0.5509
(i) w/o $\tilde{\mathbf{e}}^{\text{collab}}$	0.4448	0.6080
(j) with $\tilde{\mathbf{e}}^{\text{collab}}_{\text{rand}}$	0.4653	0.6231
(k) FLAME-LLaMA2	0.4591	0.6168
(l) FLAME-LLaMA3	0.4774	0.6344
FLAME	0.4836	0.6408




Figure 6: Training curves of GRPO and step-wise GRPO.

5.3 Ablation Study

We conduct ablations to assess the impact of each component in FLAME, including the list-wise decision model, step-wise GRPO, and multi-source knowledge fusion.

List-wise Decision Model. We first examine the roles of π_{cls} and π_{list} . Table 2 (a)-(b) shows that removing π_{cls} significantly harms performance, highlighting the importance of individualized filtering. Excluding π_{list} also degrades results, indicating that list-wise modeling is essential for capturing decision structures beyond point-wise analysis.

We further evaluate the two-stage training of π_{list} . Skipping SFT limits task-form alignment, while omitting step-wise GRPO weakens preference learning (Table 2 (c)-(d)). These results confirm the necessity of both SFT and step-wise preference alignment.

Step-wise GRPO. Replacing step-wise GRPO with standard GRPO (Table 2 (e)) results in clear performance drops, demonstrating that outcome-only rewards are insufficient. Fig. 6 shows that step-wise GRPO provides denser feedback, accelerating learning and improving stability.

Multi-source Knowledge Fusion. Integrating structured codes and unstructured clinical notes significantly boosts performance; removing either degrades results (Table 2 (f)-(g)). To analyze embedding strategies, we replace collaborative embeddings with random vectors $\tilde{\mathbf{e}}^{\text{collab}}_{\text{rand}}$. While random embeddings offer slight gains over text-only inputs, they lack meaningful domain knowledge, resulting in a notable gap from FLAME (Table 2 (h)-(j)).

LLM Backbone. Replacing the Llama3.1-Aloe-Beta-8B backbone with general large language models (LLaMA2 and LLaMA3) leads to noticeable performance drops (Table 2 (k)-(l)). This highlights the critical role of domain-specific medical knowledge embedded in Llama3.1-Aloe-Beta-8B for accurate medication recommendation.

5.4 In-Depth Analysis

To further understand the empirical behaviors of FLAME, we conduct in-depth analyses on the necessity of the list-wise refinement policy π_{list} , and the effectiveness of step-wise GRPO. These analyses complement the quantitative results and provide qualitative evidence for our design choices.

Role of the List-wise Policy π_{list} . In Table 2(b), removing π_{list} results in a relatively small numerical drop (Jaccard $0.4836 \rightarrow 0.4785$), which may appear marginal at first glance. However, this is expected, since π_{list} acts as a *lightweight refinement module* rather than a primary predictor. On the MIMIC-III test set, π_{cls} outputs lists of average length 20.83, while π_{list} performs only ~ 2.03

add/remove edits per patient on average. These small-scale edits are crucial: they primarily resolve subtle drug–drug dependencies and redundancies that point-wise classifiers cannot capture.

We identify two major benefits of π_{list} . (1) *Safety–accuracy controllability*. π_{cls} is optimized to mimic ground truth prescriptions, producing DDI rates (0.1336) close to the real data distribution (0.1369). While effective for data fitting, this limits its ability to adapt to stricter safety constraints required in real-world clinical practice. In contrast, π_{list} incorporates the safety penalty α (Eq. 8), enabling explicit and controllable adjustment of safety levels. (2) *Modeling drug dependencies*. Since π_{cls} predicts each drug independently, it cannot capture co-prescription patterns or redundancies. For instance, *Piperacillin* (ID 130) is a broad-spectrum β -lactam antibiotic overlapping in indication with *Cefepime* (ID 92), *Meropenem* (ID 45), and *Ampicillin* (ID 113). In such cases, π_{cls} may recommend redundant combinations or omit suitable alternatives. By performing list-level reasoning, π_{list} corrects these issues effectively: across the test set, it edited 28 Piperacillin-containing lists with an 89% correctness rate, demonstrating its capacity for meaningful refinement beyond point-wise learning.

Table 3: Examples of π_{list} refinements. IDs **45**, **92**, **113**, and **130** denote antibiotics with overlapping effects. **Correct**, **over-predicted**, and **missing** drugs are colored **green**, **red** and **blue**, respectively. Drugs in parentheses indicate those absent from $\mathcal{M}_p$ but present in the ground truth list.

Case ID	π_{cls} Output $\mathcal{M}_p$	π_{list} Refinement
266	30, 76, 113 , 137, 6, 74, 130 , (14, 104, 114), ...	add: 14, 114; remove: 130
887	2, 71, 99, 8, 22, 130 , (34, 48, 57, 80, 92 , 126), ...	add: 34, 48, 57, 92 ; remove: 130

As shown in Table 3, π_{list} rectifies redundant and missing predictions by exploiting list-wise signals. In Case 266, π_{cls} simultaneously predicts IDs 113 and 130, which share overlapping effects, while omitting several relevant items. π_{list} removes the redundant 130 and adds the missing entries, thereby enhancing the precision of the generated medication list. In Case 887, the point-wise model again over-predicts 130 and misses 92, two drugs with overlapping indications, while π_{list} corrects both errors through list-level reasoning. These examples demonstrate that even lightweight list-wise edits can yield clinically coherent refinements by leveraging inter-drug dependencies absent in point-wise prediction, confirming the essential role of π_{list} beyond its modest aggregate numerical gain.

Effectiveness of Step-wise GRPO. Step-wise GRPO is the optimization backbone for π_{list} . While the absolute improvement over standard GRPO in Table 2(e) is modest, the relative effect is substantial: list-wise refinement’s advantage over point-wise classification increases from 0.0028 (standard GRPO) to 0.0051 (step-wise GRPO), an 82.1% relative gain. Additionally, Fig. 6 shows faster reward convergence and more stable training dynamics under step-wise GRPO, owing to its denser intermediate feedback rather than reliance on terminal rewards—an important trait for long edit sequences such as medication list refinement.

6 Conclusion

We presented FLAME, an LLM-based list-wise medication recommendation framework that formulates prescription generation as a sequential *drug-by-drug* decision process. By introducing **step-wise GRPO** with potential-based reward shaping, FLAME enables fine-grained credit assignment, effectively capturing drug interactions and enforcing safety constraints such as DDIs. Through hybrid representations that fuse structured clinical data, collaborative signals, and unstructured textual information, FLAME enhances the LLM’s capacity for accurate and clinically grounded recommendations. Extensive experiments demonstrate FLAME’s superior accuracy, controllable safety–accuracy trade-offs, and strong generalization across temporal and institutional shifts. These results highlight the potential of fine-grained list-wise alignment for building reliable, adaptable clinical decision support systems. In future work, we plan to further improve FLAME’s generalization in diverse and evolving healthcare environments, advancing towards scalable and equitable AI-driven solutions for real-world clinical practice. In addition, we will explore the integration of physician decisions with FLAME to build a human-in-the-loop medication recommendation system.

Acknowledgments

This work is supported by the National Natural Science Foundation of China (62272437,62402470), the University Synergy Innovation Program of Anhui Province (GXXT-2023-071), Anhui Provincial Natural Science Foundation (2408085QF189), and the advanced computing resources provided by the Supercomputing Center of the USTC.

References

- [1] Z. Ali, Y. Huang, I. Ullah, J. Feng, C. Deng, N. Thierry, A. Khan, A. U. Jan, X. Shen, W. Rui, *et al.*, “Deep learning for medication recommendation: a systematic survey,” *Data Intelligence*, vol. 5, no. 2, pp. 303–354, 2023.
- [2] H. Sun, S. Xie, S. Li, Y. Chen, J.-R. Wen, and R. Yan, “Debiased, longitudinal and coordinated drug recommendation through multi-visit clinic records,” *Advances in Neural Information Processing Systems*, vol. 35, pp. 27837–27849, 2022.
- [3] C. Yang, C. Xiao, F. Ma, L. Glass, and J. Sun, “Safedrug: Dual molecular graph encoders for recommending effective and safe drug combinations,” in *30th International Joint Conference on Artificial Intelligence, IJCAI 2021*, pp. 3735–3741, International Joint Conferences on Artificial Intelligence, 2021.
- [4] R. Wu, Z. Qiu, J. Jiang, G. Qi, and X. Wu, “Conditional generation net for medication recommendation,” in *Proceedings of the ACM web conference 2022*, pp. 935–945, 2022.
- [5] Z. Zhao, Y. Jing, F. Feng, J. Wu, C. Gao, and X. He, “Leave no patient behind: Enhancing medication recommendation for rare disease patients,” in *Proceedings of the 47th International ACM SIGIR Conference on Research and Development in Information Retrieval*, pp. 533–542, 2024.
- [6] Y. Zhang, R. Chen, J. Tang, W. F. Stewart, and J. Sun, “Leap: learning to prescribe effective and safe treatment combinations for multimorbidity,” in *proceedings of the 23rd ACM SIGKDD international conference on knowledge Discovery and data Mining*, pp. 1315–1324, 2017.
- [7] J. Shang, C. Xiao, T. Ma, H. Li, and J. Sun, “Gamenet: Graph augmented memory networks for recommending medication combination,” in *proceedings of the AAAI Conference on Artificial Intelligence*, vol. 33, pp. 1126–1133, 2019.
- [8] N. Yang, K. Zeng, Q. Wu, and J. Yan, “Molerec: Combinatorial drug recommendation with substructure-aware molecular representation learning,” in *Proceedings of the ACM web conference 2023*, pp. 4075–4085, 2023.
- [9] K. Singhal, S. Azizi, T. Tu, S. S. Mahdavi, J. Wei, H. W. Chung, N. Scales, A. Tanwani, H. Cole-Lewis, S. Pfohl, *et al.*, “Large language models encode clinical knowledge,” *Nature*, vol. 620, no. 7972, pp. 172–180, 2023.
- [10] Z. Zhao, C. Fan, C. Gao, F. Feng, and X. He, “Addressing overprescribing challenges: Fine-tuning large language models for medication recommendation tasks,” *arXiv preprint arXiv:2503.03687*, 2025.
- [11] N. P. Tatonetti, P. P. Ye, R. Daneshjou, and R. B. Altman, “Data-driven prediction of drug effects and interactions,” *Science translational medicine*, vol. 4, no. 125, pp. 125ra31–125ra31, 2012.
- [12] Z. Shao, P. Wang, Q. Zhu, R. Xu, J. Song, X. Bi, H. Zhang, M. Zhang, Y. Li, Y. Wu, *et al.*, “Deepseekmath: Pushing the limits of mathematical reasoning in open language models,” *arXiv preprint arXiv:2402.03300*, 2024.
- [13] A. K. Gururajan, E. Lopez-Cuena, J. Bayarri-Planas, A. Tormos, D. Hinjos, P. Bernabeu-Perez, A. Arias-Duart, P. A. Martin-Torres, L. Urcelay-Ganzabal, M. Gonzalez-Mallo, *et al.*, “Aloe: A family of fine-tuned open healthcare llms,” *arXiv preprint arXiv:2405.01886*, 2024.
- [14] A. E. Johnson, T. J. Pollard, L. Shen, L.-w. H. Lehman, M. Feng, M. Ghassemi, B. Moody, P. Szolovits, L. Anthony Celi, and R. G. Mark, “Mimic-iii, a freely accessible critical care database,” *Scientific data*, vol. 3, no. 1, pp. 1–9, 2016.
- [15] A. E. Johnson, L. Bulgarelli, L. Shen, A. Gayles, A. Shammout, S. Horng, T. J. Pollard, S. Hao, B. Moody, B. Gow, *et al.*, “Mimic-iv, a freely accessible electronic health record dataset,” *Scientific data*, vol. 10, no. 1, p. 1, 2023.

- [16] T. J. Pollard, A. E. Johnson, J. D. Raffa, L. A. Celi, R. G. Mark, and O. Badawi, “The eicu collaborative research database, a freely available multi-center database for critical care research,” *Scientific data*, vol. 5, no. 1, pp. 1–13, 2018.
- [17] J. Tan, Y. Rong, K. Zhao, T. Bian, T. Xu, J. Huang, H. Cheng, and H. Meng, “Natural language-assisted multi-modal medication recommendation,” in *Proceedings of the 33rd ACM International Conference on Information and Knowledge Management*, pp. 2200–2209, 2024.
- [18] C. Gao, R. Chen, S. Yuan, K. Huang, Y. Yu, and X. He, “Sprec: Self-play to debias llm-based recommendation,” in *Proceedings of the ACM on Web Conference 2025*, pp. 5075–5084, 2025.
- [19] C. Gao, S. Wang, S. Li, J. Chen, X. He, W. Lei, B. Li, Y. Zhang, and P. Jiang, “Cirs: Bursting filter bubbles by counterfactual interactive recommender system,” *ACM Transactions on Information Systems*, vol. 42, no. 1, pp. 1–27, 2023.
- [20] S. Lin, C. Gao, J. Chen, S. Zhou, B. Hu, Y. Feng, C. Chen, and C. Wang, “How do recommendation models amplify popularity bias? an analysis from the spectral perspective,” in *Proceedings of the Eighteenth ACM International Conference on Web Search and Data Mining, WSDM '25*, p. 659–668, 2025.
- [21] J. Schulman, F. Wolski, P. Dhariwal, A. Radford, and O. Klimov, “Proximal policy optimization algorithms,” *arXiv preprint arXiv:1707.06347*, 2017.
- [22] R. Rafailov, A. Sharma, E. Mitchell, C. D. Manning, S. Ermon, and C. Finn, “Direct preference optimization: Your language model is secretly a reward model,” *Advances in Neural Information Processing Systems*, vol. 36, pp. 53728–53741, 2023.
- [23] Q. Yu, Z. Zhang, R. Zhu, Y. Yuan, X. Zuo, Y. Yue, W. Dai, T. Fan, G. Liu, L. Liu, *et al.*, “Dapo: An open-source llm reinforcement learning system at scale,” *arXiv preprint arXiv:2503.14476*, 2025.
- [24] J. Zhang, J. Huang, H. Yao, S. Liu, X. Zhang, S. Lu, and D. Tao, “R1-vl: Learning to reason with multimodal large language models via step-wise group relative policy optimization,” *arXiv preprint arXiv:2503.12937*, 2025.
- [25] M. R. Cowie, J. I. Blomster, L. H. Curtis, S. Duclaux, I. Ford, F. Fritz, S. Goldman, S. Janmohamed, J. Kreuzer, M. Leenay, *et al.*, “Electronic health records to facilitate clinical research,” *Clinical Research in Cardiology*, vol. 106, pp. 1–9, 2017.
- [26] C. Gao, M. Gao, C. Fan, S. Yuan, W. Shi, and X. He, “Process-supervised llm recommenders via flow-guided tuning,” in *Proceedings of the 48th International ACM SIGIR Conference on Research and Development in Information Retrieval*, pp. 1934–1943, 2025.
- [27] A. Y. Ng, D. Harada, and S. Russell, “Policy invariance under reward transformations: Theory and application to reward shaping,” in *ICML*, pp. 278–287, Morgan Kaufmann, 1999.
- [28] R. Rafailov, J. Hejna, R. Park, and C. Finn, “From r to q*: Your language model is secretly a q-function,” *arXiv preprint arXiv:2404.12358*, 2024.
- [29] Y. Zhang, F. Feng, J. Zhang, K. Bao, Q. Wang, and X. He, “Collm: Integrating collaborative embeddings into large language models for recommendation,” *IEEE Transactions on Knowledge and Data Engineering*, 2025.
- [30] J. Liao, S. Li, Z. Yang, J. Wu, Y. Yuan, X. Wang, and X. He, “Llara: Large language-recommendation assistant,” in *Proceedings of the 47th International ACM SIGIR Conference on Research and Development in Information Retrieval*, pp. 1785–1795, 2024.
- [31] C. Yang, C. Xiao, L. Glass, and J. Sun, “Change matters: Medication change prediction with recurrent residual networks,” *arXiv preprint arXiv:2105.01876*, 2021.
- [32] J. Xia, C. Zhao, B. Hu, Z. Gao, C. Tan, Y. Liu, S. Li, and S. Z. Li, “Mole-bert: Rethinking pre-training graph neural networks for molecules,” 2023.

A Theoretical Analysis

Proof. We prove the theorem using the reward shaping framework introduced by [27], which shows that augmenting a reward function with a potential-based shaping term does not alter the optimal policy.

Lemma A.1 (Ng et al., 1999). *Let $r(s_t, a_t)$ and $r'(s_t, a_t)$ be two reward functions. If there exists a potential function $\Phi(s)$ such that:*

$$r'(s_t, a_t) = r(s_t, a_t) + \gamma\Phi(s_{t+1}) - \Phi(s_t), \quad (17)$$

where γ is the discount factor, then the optimal policies under r and r' are identical.

Now, consider the outcome-based reward:

$$r_{i,t}^{\text{terminal}} = \begin{cases} \varphi(J_i), & \text{if } t \text{ is terminal,} \\ 0, & \text{otherwise.} \end{cases}$$

We define the shaped step-wise reward as:

$$r_{i,t}^{\text{step}} = \varphi(\text{step}(t)) - \varphi(\text{step}(t) - 1).$$

Let us define a potential function $\Phi(t) = \varphi(\text{step}(t))$. Then the step-wise reward can be rewritten as:

$$r_{i,t}^{\text{step}} = \Phi(t) - \Phi(t - 1).$$

Summing over the episode:

$$\sum_{t=1}^T r_{i,t}^{\text{step}} = \Phi(T) - \Phi(0) = \varphi(J_i) - \varphi(0),$$

assuming $\text{step}(T) = J_i$. Since $\varphi(0)$ is constant across all trajectories, it does not affect the optimization. Thus, both reward schemes only differ by a constant shift and a potential-based shaping term.

By the lemma, such a transformation does not change the optimal policy.

Conclusion: The outcome-based terminal reward and the shaped step-wise reward are equivalent in terms of the policies they induce. $\square$

B Dataset Details

B.1 Data Preprocessing

We follow the data preprocessing procedures adopted in prior work [10], using structured and unstructured EHR data from the MIMIC-III [14] database. For structured clinical information, we extract diagnosis and procedure codes and retrieve their corresponding textual descriptions from the ICD dictionary tables. Since the original long titles in the dictionary can be overly verbose and difficult for LLMs to process, we utilize GPT-4o to compress them into concise titles while preserving the essential semantic content. This compression strategy follows the same approach as adopted in LAMO [10] to ensure semantic integrity and model compatibility.

For medication data, we map National Drug Codes to DrugBank IDs and obtain associated text descriptions from corresponding lookup tables. To incorporate unstructured information, we follow the previous pipeline and extract segments from clinical notes, including **History of Present Illness**, **Past Medical History**, **Allergies**, and **Medications on Admission**, using GPT-4o as a parser to construct patient condition descriptions. A representative example of unstructured text extracted from clinical notes is shown below:

Example of unstructured text extracted from clinical notes

History of Present Illness: The patient is a 66-year-old female with a history of breast cancer and recent onset ascites and pelvic mass. She presented with worsening abdominal discomfort, poor oral intake, and dyspnea.

Past Medical History: The patient has a history of breast cancer, hypertension, hypothyroidism, tubal ligation, and a previous metacarpal fracture.

Allergies: [codeine].

Medications on Admission: [Lisinopril, Effexor, Levoxyl, Tamoxifen, Fosamax].

B.2 Dataset Statistics

After preprocessing the structured clinical codes (diagnoses, procedures, and medications), we obtain the dataset statistics summarized in Table 4.

Table 4: Statistics of processed data in MIMIC-III

Items	MIMIC-III
# of visits / # of patients	14207 / 6226
dis. / prod. / med. space size	1676 / 511 / 151
avg. / max # of visits	2.28 / 29
avg. / max # of dis. per visit	13.59 / 39
avg. / max # of pro. per visit	4.23 / 27
avg. / max # of med. per visit	23.36 / 77

C Experimental Setup

C.1 Training Details and Hyperparameters

We conduct all experiments on NVIDIA A100-SXM4-80GB GPUs, with Python 3.10 and PyTorch 2.5.1. During all training stages, the model is quantized using bf16 and LoRA, and optimized using the `adamw_torch` optimizer.

For the SFT of drug-level classifier π_{cls} , we use Llama3-Aloe-8B-Alpha as the base model. Four projectors are randomly initialized: `pat_projector`, `diag_projector`, `pro_projector`, and `med_projector`, each consisting of a two-layer MLP with GELU activation. The learning rate is set to $5e-4$, with a batch size of 128 and one epoch.

For the SFT of list-wise policy π_{list} , the model and projector weights from the previous step (π_{cls}) are used as initialization. The learning rate remains $5e-4$, with a batch size of 64 and one epoch.

When performing step-wise GRPO on π_{list} , we initialize the model and projector weights from the previous SFT step. The projector parameter ‘`r_grad`’ is set to False. We use the Unsloth framework and vLLM 0.7.3 for acceleration. The learning rate is set to $1e-5$, with a batch size of 16, ‘`num_generations`’ set to 8, and one epoch. The hyperparameter α is chosen from the set [0, 2, 5, 10, 20, 30, 40, 50] to adapt to different DDI requirements, while β is set to 0.5, and λ is set to 5.

C.2 Baseline Methods and Evaluation Metrics

We provide a comprehensive overview of baseline models that have been widely used for the medication recommendation task:

- **LEAP** [6] formulates the medication prediction task using only the current visit and models label dependencies via multi-instance multi-label learning.
- **GAMENet** [7] integrates EHR and DDI graphs via graph-augmented memory networks to ensure both accuracy and safety.

- **SafeDrug** [3] employs dual molecular encoders to learn molecular representations and improve safe prescription decisions.
- **COGNet** [4] leverages a copy-or-predict mechanism to incorporate historical prescriptions into current decision making.
- **MICRON** [31] introduces a recurrent residual learning model that treats medication change dynamics as the primary learning target.
- **MoleRec** [8] proposes a substructure-aware attention mechanism that models drug substructure–patient condition interactions at a fine-grained level.
- **RAREMed** [5] utilizes a Transformer-based encoder to derive comprehensive patient representations and mitigate fairness issues in recommendation.
- **NLA-MMR** [17] designs a multi-modal alignment framework to jointly encode patient and medication representations across modalities.
- **LAMO** [10] builds on LLaMA-2 and incorporates unstructured clinical notes to better capture the patient’s condition, leveraging the semantic understanding capabilities of LLMs for accurate medication recommendation.

We adopt Jaccard Score and F1 Score to evaluate the prediction accuracy, and DDI rate to assess the safety of recommended medication sets. Given the model prediction $\mathcal{M}_v$ and the ground-truth set $\mathcal{M}_{GT}$, we define:

- **Jaccard Score:**

$$\text{Jaccard}(\mathcal{M}_v, \mathcal{M}_{GT}) = \frac{|\mathcal{M}_v \cap \mathcal{M}_{GT}|}{|\mathcal{M}_v \cup \mathcal{M}_{GT}|} \quad (18)$$

- **F1 Score**, computed based on precision and recall:

$$\text{Precision} = \frac{|\mathcal{M}_v \cap \mathcal{M}_{GT}|}{|\mathcal{M}_v|}, \quad \text{Recall} = \frac{|\mathcal{M}_v \cap \mathcal{M}_{GT}|}{|\mathcal{M}_{GT}|}, \quad \text{F1} = \frac{2 \cdot \text{Precision} \cdot \text{Recall}}{\text{Precision} + \text{Recall}} \quad (19)$$

- **DDI rate** measures the ratio of harmful drug-drug interactions among predicted medications:

$$\text{DDI}(\mathcal{M}_v, \mathbf{D}) = \frac{|\{(d_i, d_j) \mid d_i, d_j \in \mathcal{M}_v, i < j, \mathbf{D}[d_i, d_j] = 1\}|}{\binom{|\mathcal{M}_v|}{2}} \quad (20)$$

C.3 Prompt Templates

In Section 4.3, we propose a two-stage recommendation framework, which consists of: (1) drug-level filtering and (2) list-level refinement. Below we provide the prompt templates used in each stage.

For the drug-level classifier (π_{cls}), we formulate a binary classification task over each candidate drug $m \in \mathcal{M}_c$ in the set of drug candidates. Each drug is evaluated independently based on its appropriateness for the given patient. The model is prompted with the patient’s clinical representation and a textual description of the candidate drug. Specifically, `{{Patient Representation}}` includes both patient’s current status and previous hospitalization records. `{{Drug Candidate}}` refers to the textual representation of a single drug under evaluation.

Prompt Template for Drug-level Filtering

You are about to evaluate a candidate drug for a patient’s clinical condition. You will be provided with the patient’s current condition, as well as information about their previous hospitalization, and the candidate drug. Your task is to determine whether the candidate drug is effective and safe for the patient. Please respond with <Yes.> or <No.> without providing an explanation.

`{{Patient Representation}}`

Candidate drug: `{{Drug Candidates}}`

###Answer:

For the list-level refinement policy (π_{list}), we further optimize the drug set $\mathcal{M}_p$ produced by the drug-level classifier by modeling dependencies among drugs and refining the list through two complementary tasks: (1) adding missing yet clinically necessary drugs, and (2) removing drugs that are unnecessary or potentially unsafe for the patient. Each task is formulated as a separate prompt, where the model is asked to revise a pre-predicted drug list based on the patient's condition and medical history.

The task instruction is injected into the prompt through the `{{instruction}}` placeholder, with the following two variants:

- **Add task:** add any relevant drugs that are missing from the pre-predicted list.
- **Remove task:** remove any drugs from the pre-predicted list that are unnecessary or unsuitable for the patient's condition.

The unified prompt template used in both tasks is shown below:

Prompt Template for List-level Refinement

You are tasked with refining a drug list for a patient's clinical condition. You will be provided with the patient's condition, information about their previous hospitalization and a pre-predicted drug list.
Your task is to: `{{instruction}}`
Please output a list of drugs that need to be `{{added or removed}}`, with each drug separated by a newline.
`{{Patient Representation}}`
###Pre-predicted Drug List: `{{Mp}}`
###Drugs to `{{Add or Remove}}`:

To enable comprehensive modeling of the patient's condition within each task prompt, we incorporate both current and historical clinical information into the `{{Patient Representation}}` field whenever available. Specifically, we differentiate between patients with and without prior hospitalization records. The formatting is as follows:

Prompt Template for Patient Representation

For patients with previous hospitalization records:
Previous Hospitalization: `{{Previous Representation}}`
Current Clinical Condition: `{{Current Representation}}`

For patients without previous hospitalization records:
Current Clinical Condition: `{{Current Representation}}`

For the patient's previous hospitalization representation `{{Previous Representation}}`, we construct a hybrid representation that integrates structured information from diagnoses, procedures, and medications, along with demographic data.

Prompt Template for Previous Representation

Age: `{{Age of the patient, eg. 68}}`,
Gender: `{{Patient's biological sex, e.g., Male}}`,
Diagnoses: `{{Hybrid diagnosis representation}}`,
Procedures: `{{Hybrid procedures representation}}`,
Drug names: `{{Hybrid drugs representation}}`.

Here we further describe the format of the `{{Current Representation}}`, which captures the patient's clinical status at admission. This representation integrates both structured data—such as diagnoses and procedures—and unstructured information extracted from clinical notes, including the history of present illness, past medical history, allergies, and medications on admission.

Prompt Template for Current Representation

Patient representation: `{{Latent embedding}}`,
History of present illness: `{{Unstructured text extracted from clinical notes}}`,
Past medical history: `{{Unstructured text extracted from clinical notes}}`,
Allergies: `{{Unstructured text extracted from clinical notes}}`,
Medications on admission: `{{Unstructured text extracted from clinical notes}}`,
Diagnoses: `{{Hybrid diagnosis representation}}`,
Procedures: `{{Hybrid procedures representation}}`.

As introduced in Section 4.4, our model leverages hybrid representations to encode structured EHR fields—namely diagnoses, procedures, and medications—by combining the textual representations generated by LLM with collaborative embeddings produced by domain-specific encoders. These hybrid representations correspond to the placeholder fields—Hybrid diagnosis representation, Hybrid procedures representation, and Hybrid drugs representation—previously introduced in our prompt templates. Here, we provide concrete examples of how each field is instantiated.

Specifically, for each structured medical code, we first obtain a textual description suitable for LLM input. In parallel, we apply a domain-specific encoder to the original structured code to extract a collaborative embedding, which captures latent clinical semantics. This collaborative embedding is then projected into the LLM embedding space using a learnable adapter, rather than being passed through the LLM’s standard tokenizer and embedding layer. The final hybrid representation is thus composed of both the textual token sequence and its aligned embedding enhancement. More details of this embedding alignment can be found in Section 4.4.

The following illustrates the prompt-level instantiation of hybrid representations:

Prompt-level Instantiation of Hybrid Representations

Diagnoses: Hematochezia [**DiagEmb-12**], Acute Kidney Injury [**DiagEmb-56**], Heart Failure [**DiagEmb-104**] ...
Procedures: Coronary Artery Stenting [**ProEmb-8**], Three Vessel Procedure [**ProEmb-79**], Stent Insertion [**ProEmb-226**] ...
Drug names: Calcium gluconate [**DrugEmb-2**], Captopril [**DrugEmb-31**], Magnesium sulfate [**DrugEmb-3**] ...

D Limitations

While FLAME shows promising results, it also has several limitations that warrant further investigation:

- **Computational cost and deployment challenges:** The use of LLM introduces significant training and inference overhead. This can limit the practical deployment of the system in resource-constrained clinical settings, especially in real-time or on-device applications.
- **Lack of automated multi-modal data integration:** Although our framework incorporates both structured and unstructured patient data, it currently lacks an end-to-end automated mechanism for multi-modal data processing. In particular, the handling of unstructured patient narratives relies on manually invoking external APIs (e.g., GPT-4o), which limits scalability and consistency.
- **Static evaluation setting:** Our model is trained and evaluated on static EHR datasets, which do not fully capture the dynamic nature of real-world clinical workflows. Bridging this gap requires further investigation into how such models can be adapted for continual learning or integration with live clinical decision support systems.

E Broader Impacts

This work presents the potential for significant positive societal impact by advancing the integration of LLMs into clinical decision-making. By providing accurate, context-aware, and safe medication recommendations, our framework supports physicians rather than replacing them, offering interpretable suggestions that can complement and enhance clinical judgment. This human-in-the-loop design reinforces trust and accountability in medical AI systems, ensuring that final decisions remain under professional oversight. Furthermore, the model's ability to handle both structured clinical data and unstructured free-text inputs aligns naturally with real-world clinical workflows, where critical patient information often resides in narrative form. This flexibility reduces the burden of data curation and enables more seamless adoption in practice. In addition, the model's demonstrated generalizability across time and institutional boundaries opens avenues for deployment in under-resourced settings, where access to experienced clinicians and high-quality clinical decision support is limited. By bridging this gap, our work contributes toward improving the equity and reach of healthcare services. Ultimately, we envision this research as a step toward scalable, adaptive, and collaborative AI systems that respect clinical complexity while expanding access to safe and effective medical support across diverse populations.

However, despite its potential benefits, the deployment of FLAME also poses certain societal risks. First, the model's performance may be affected by biases in the training data, which could lead to disparities in recommendation quality across different patient populations, particularly those underrepresented in historical records. Second, there is a risk of misuse if such systems are deployed without proper clinical oversight—for example, being used in unauthorized settings or for non-medical purposes, potentially leading to harmful or misleading recommendations. These concerns underscore the need for responsible deployment practices, transparency, and safeguards to ensure that FLAME is used ethically and equitably in real-world clinical environments.

NeurIPS Paper Checklist

1. Claims

Question: Do the main claims made in the abstract and introduction accurately reflect the paper's contributions and scope?

Answer: [Yes]

Justification: The abstract and introduction clearly state the key contributions of the paper, including the introduction of a list-wise decision framework (FLAME), the design of step-wise GRPO for fine-grained reward optimization, and the integration of multi-level medical knowledge. These are all reflected in the method and validated through extensive experiments, matching both the theoretical and empirical scope of the work.

Guidelines:

- The answer NA means that the abstract and introduction do not include the claims made in the paper.
- The abstract and/or introduction should clearly state the claims made, including the contributions made in the paper and important assumptions and limitations. A No or NA answer to this question will not be perceived well by the reviewers.
- The claims made should match theoretical and experimental results, and reflect how much the results can be expected to generalize to other settings.
- It is fine to include aspirational goals as motivation as long as it is clear that these goals are not attained by the paper.

2. Limitations

Question: Does the paper discuss the limitations of the work performed by the authors?

Answer: [Yes]

Justification: Provided in the appendix.

Guidelines:

- The answer NA means that the paper has no limitation while the answer No means that the paper has limitations, but those are not discussed in the paper.
- The authors are encouraged to create a separate "Limitations" section in their paper.
- The paper should point out any strong assumptions and how robust the results are to violations of these assumptions (e.g., independence assumptions, noiseless settings, model well-specification, asymptotic approximations only holding locally). The authors should reflect on how these assumptions might be violated in practice and what the implications would be.
- The authors should reflect on the scope of the claims made, e.g., if the approach was only tested on a few datasets or with a few runs. In general, empirical results often depend on implicit assumptions, which should be articulated.
- The authors should reflect on the factors that influence the performance of the approach. For example, a facial recognition algorithm may perform poorly when image resolution is low or images are taken in low lighting. Or a speech-to-text system might not be used reliably to provide closed captions for online lectures because it fails to handle technical jargon.
- The authors should discuss the computational efficiency of the proposed algorithms and how they scale with dataset size.
- If applicable, the authors should discuss possible limitations of their approach to address problems of privacy and fairness.
- While the authors might fear that complete honesty about limitations might be used by reviewers as grounds for rejection, a worse outcome might be that reviewers discover limitations that aren't acknowledged in the paper. The authors should use their best judgment and recognize that individual actions in favor of transparency play an important role in developing norms that preserve the integrity of the community. Reviewers will be specifically instructed to not penalize honesty concerning limitations.

3. Theory assumptions and proofs

Question: For each theoretical result, does the paper provide the full set of assumptions and a complete (and correct) proof?

Answer: [Yes]

Justification: The paper provides Theorem 1 with all necessary assumptions explicitly stated, and its proof is included in Appendix A.

Guidelines:

- The answer NA means that the paper does not include theoretical results.
- All the theorems, formulas, and proofs in the paper should be numbered and cross-referenced.
- All assumptions should be clearly stated or referenced in the statement of any theorems.
- The proofs can either appear in the main paper or the supplemental material, but if they appear in the supplemental material, the authors are encouraged to provide a short proof sketch to provide intuition.
- Inversely, any informal proof provided in the core of the paper should be complemented by formal proofs provided in appendix or supplemental material.
- Theorems and Lemmas that the proof relies upon should be properly referenced.

4. Experimental result reproducibility

Question: Does the paper fully disclose all the information needed to reproduce the main experimental results of the paper to the extent that it affects the main claims and/or conclusions of the paper (regardless of whether the code and data are provided or not)?

Answer: [Yes]

Justification: We provide the code to reproduce the experimental results, and include detailed descriptions of hyperparameter settings and prompts in the appendix to ensure reproducibility.

Guidelines:

- The answer NA means that the paper does not include experiments.
- If the paper includes experiments, a No answer to this question will not be perceived well by the reviewers: Making the paper reproducible is important, regardless of whether the code and data are provided or not.
- If the contribution is a dataset and/or model, the authors should describe the steps taken to make their results reproducible or verifiable.
- Depending on the contribution, reproducibility can be accomplished in various ways. For example, if the contribution is a novel architecture, describing the architecture fully might suffice, or if the contribution is a specific model and empirical evaluation, it may be necessary to either make it possible for others to replicate the model with the same dataset, or provide access to the model. In general, releasing code and data is often one good way to accomplish this, but reproducibility can also be provided via detailed instructions for how to replicate the results, access to a hosted model (e.g., in the case of a large language model), releasing of a model checkpoint, or other means that are appropriate to the research performed.
- While NeurIPS does not require releasing code, the conference does require all submissions to provide some reasonable avenue for reproducibility, which may depend on the nature of the contribution. For example
 - (a) If the contribution is primarily a new algorithm, the paper should make it clear how to reproduce that algorithm.
 - (b) If the contribution is primarily a new model architecture, the paper should describe the architecture clearly and fully.
 - (c) If the contribution is a new model (e.g., a large language model), then there should either be a way to access this model for reproducing the results or a way to reproduce the model (e.g., with an open-source dataset or instructions for how to construct the dataset).
 - (d) We recognize that reproducibility may be tricky in some cases, in which case authors are welcome to describe the particular way they provide for reproducibility. In the case of closed-source models, it may be that access to the model is limited in

some way (e.g., to registered users), but it should be possible for other researchers to have some path to reproducing or verifying the results.

5. Open access to data and code

Question: Does the paper provide open access to the data and code, with sufficient instructions to faithfully reproduce the main experimental results, as described in supplemental material?

Answer: [\[Yes\]](#)

Justification: We provide the code for reproducing experimental results, including scripts for processing the EHR datasets. Detailed instructions are included in the supplemental material to ensure faithful reproduction.

Guidelines:

- The answer NA means that paper does not include experiments requiring code.
- Please see the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- While we encourage the release of code and data, we understand that this might not be possible, so “No” is an acceptable answer. Papers cannot be rejected simply for not including code, unless this is central to the contribution (e.g., for a new open-source benchmark).
- The instructions should contain the exact command and environment needed to run to reproduce the results. See the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- The authors should provide instructions on data access and preparation, including how to access the raw data, preprocessed data, intermediate data, and generated data, etc.
- The authors should provide scripts to reproduce all experimental results for the new proposed method and baselines. If only a subset of experiments are reproducible, they should state which ones are omitted from the script and why.
- At submission time, to preserve anonymity, the authors should release anonymized versions (if applicable).
- Providing as much information as possible in supplemental material (appended to the paper) is recommended, but including URLs to data and code is permitted.

6. Experimental setting/details

Question: Does the paper specify all the training and test details (e.g., data splits, hyperparameters, how they were chosen, type of optimizer, etc.) necessary to understand the results?

Answer: [\[Yes\]](#)

Justification: Full details are provided in the appendix to ensure clarity and reproducibility.

Guidelines:

- The answer NA means that the paper does not include experiments.
- The experimental setting should be presented in the core of the paper to a level of detail that is necessary to appreciate the results and make sense of them.
- The full details can be provided either with the code, in appendix, or as supplemental material.

7. Experiment statistical significance

Question: Does the paper report error bars suitably and correctly defined or other appropriate information about the statistical significance of the experiments?

Answer: [\[No\]](#)

Justification: We did not perform statistical significance tests due to compute and time constraints, but ablation studies support the validity of our key findings.

Guidelines:

- The answer NA means that the paper does not include experiments.

- The authors should answer "Yes" if the results are accompanied by error bars, confidence intervals, or statistical significance tests, at least for the experiments that support the main claims of the paper.
- The factors of variability that the error bars are capturing should be clearly stated (for example, train/test split, initialization, random drawing of some parameter, or overall run with given experimental conditions).
- The method for calculating the error bars should be explained (closed form formula, call to a library function, bootstrap, etc.)
- The assumptions made should be given (e.g., Normally distributed errors).
- It should be clear whether the error bar is the standard deviation or the standard error of the mean.
- It is OK to report 1-sigma error bars, but one should state it. The authors should preferably report a 2-sigma error bar than state that they have a 96% CI, if the hypothesis of Normality of errors is not verified.
- For asymmetric distributions, the authors should be careful not to show in tables or figures symmetric error bars that would yield results that are out of range (e.g. negative error rates).
- If error bars are reported in tables or plots, The authors should explain in the text how they were calculated and reference the corresponding figures or tables in the text.

8. Experiments compute resources

Question: For each experiment, does the paper provide sufficient information on the computer resources (type of compute workers, memory, time of execution) needed to reproduce the experiments?

Answer: [Yes]

Justification: Provided in the appendix.

Guidelines:

- The answer NA means that the paper does not include experiments.
- The paper should indicate the type of compute workers CPU or GPU, internal cluster, or cloud provider, including relevant memory and storage.
- The paper should provide the amount of compute required for each of the individual experimental runs as well as estimate the total compute.
- The paper should disclose whether the full research project required more compute than the experiments reported in the paper (e.g., preliminary or failed experiments that didn't make it into the paper).

9. Code of ethics

Question: Does the research conducted in the paper conform, in every respect, with the NeurIPS Code of Ethics <https://neurips.cc/public/EthicsGuidelines>?

Answer: [Yes]

Justification: Fully compliant with the NeurIPS Code of Ethics.

Guidelines:

- The answer NA means that the authors have not reviewed the NeurIPS Code of Ethics.
- If the authors answer No, they should explain the special circumstances that require a deviation from the Code of Ethics.
- The authors should make sure to preserve anonymity (e.g., if there is a special consideration due to laws or regulations in their jurisdiction).

10. Broader impacts

Question: Does the paper discuss both potential positive societal impacts and negative societal impacts of the work performed?

Answer: [Yes]

Justification: We briefly mention the societal impact in the conclusion and provide a more detailed discussion in the appendix.

Guidelines:

- The answer NA means that there is no societal impact of the work performed.
- If the authors answer NA or No, they should explain why their work has no societal impact or why the paper does not address societal impact.
- Examples of negative societal impacts include potential malicious or unintended uses (e.g., disinformation, generating fake profiles, surveillance), fairness considerations (e.g., deployment of technologies that could make decisions that unfairly impact specific groups), privacy considerations, and security considerations.
- The conference expects that many papers will be foundational research and not tied to particular applications, let alone deployments. However, if there is a direct path to any negative applications, the authors should point it out. For example, it is legitimate to point out that an improvement in the quality of generative models could be used to generate deepfakes for disinformation. On the other hand, it is not needed to point out that a generic algorithm for optimizing neural networks could enable people to train models that generate Deepfakes faster.
- The authors should consider possible harms that could arise when the technology is being used as intended and functioning correctly, harms that could arise when the technology is being used as intended but gives incorrect results, and harms following from (intentional or unintentional) misuse of the technology.
- If there are negative societal impacts, the authors could also discuss possible mitigation strategies (e.g., gated release of models, providing defenses in addition to attacks, mechanisms for monitoring misuse, mechanisms to monitor how a system learns from feedback over time, improving the efficiency and accessibility of ML).

11. Safeguards

Question: Does the paper describe safeguards that have been put in place for responsible release of data or models that have a high risk for misuse (e.g., pretrained language models, image generators, or scraped datasets)?

Answer: [NA]

Justification: Our work does not release high-risk data or model artifacts.

Guidelines:

- The answer NA means that the paper poses no such risks.
- Released models that have a high risk for misuse or dual-use should be released with necessary safeguards to allow for controlled use of the model, for example by requiring that users adhere to usage guidelines or restrictions to access the model or implementing safety filters.
- Datasets that have been scraped from the Internet could pose safety risks. The authors should describe how they avoided releasing unsafe images.
- We recognize that providing effective safeguards is challenging, and many papers do not require this, but we encourage authors to take this into account and make a best faith effort.

12. Licenses for existing assets

Question: Are the creators or original owners of assets (e.g., code, data, models), used in the paper, properly credited and are the license and terms of use explicitly mentioned and properly respected?

Answer: [Yes]

Justification: We cite the dataset and respect its usage license and terms.

Guidelines:

- The answer NA means that the paper does not use existing assets.
- The authors should cite the original paper that produced the code package or dataset.
- The authors should state which version of the asset is used and, if possible, include a URL.
- The name of the license (e.g., CC-BY 4.0) should be included for each asset.

- For scraped data from a particular source (e.g., website), the copyright and terms of service of that source should be provided.
- If assets are released, the license, copyright information, and terms of use in the package should be provided. For popular datasets, paperswithcode.com/datasets has curated licenses for some datasets. Their licensing guide can help determine the license of a dataset.
- For existing datasets that are re-packaged, both the original license and the license of the derived asset (if it has changed) should be provided.
- If this information is not available online, the authors are encouraged to reach out to the asset's creators.

13. **New assets**

Question: Are new assets introduced in the paper well documented and is the documentation provided alongside the assets?

Answer: [\[Yes\]](#)

Justification: Code is released with documentation and anonymized link.

Guidelines:

- The answer NA means that the paper does not release new assets.
- Researchers should communicate the details of the dataset/code/model as part of their submissions via structured templates. This includes details about training, license, limitations, etc.
- The paper should discuss whether and how consent was obtained from people whose asset is used.
- At submission time, remember to anonymize your assets (if applicable). You can either create an anonymized URL or include an anonymized zip file.

14. **Crowdsourcing and research with human subjects**

Question: For crowdsourcing experiments and research with human subjects, does the paper include the full text of instructions given to participants and screenshots, if applicable, as well as details about compensation (if any)?

Answer: [\[NA\]](#)

Justification: This paper does not involve crowdsourcing or any research with human subjects.

Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.
- Including this information in the supplemental material is fine, but if the main contribution of the paper involves human subjects, then as much detail as possible should be included in the main paper.
- According to the NeurIPS Code of Ethics, workers involved in data collection, curation, or other labor should be paid at least the minimum wage in the country of the data collector.

15. **Institutional review board (IRB) approvals or equivalent for research with human subjects**

Question: Does the paper describe potential risks incurred by study participants, whether such risks were disclosed to the subjects, and whether Institutional Review Board (IRB) approvals (or an equivalent approval/review based on the requirements of your country or institution) were obtained?

Answer: [\[NA\]](#)

Justification: This study does not involve crowdsourcing or research with human subjects, and therefore does not require IRB or equivalent approval.

Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.

- Depending on the country in which research is conducted, IRB approval (or equivalent) may be required for any human subjects research. If you obtained IRB approval, you should clearly state this in the paper.
- We recognize that the procedures for this may vary significantly between institutions and locations, and we expect authors to adhere to the NeurIPS Code of Ethics and the guidelines for their institution.
- For initial submissions, do not include any information that would break anonymity (if applicable), such as the institution conducting the review.

16. **Declaration of LLM usage**

Question: Does the paper describe the usage of LLMs if it is an important, original, or non-standard component of the core methods in this research? Note that if the LLM is used only for writing, editing, or formatting purposes and does not impact the core methodology, scientific rigorousness, or originality of the research, declaration is not required.

Answer: [\[Yes\]](#)

Justification: The LLM is an essential part of our core methodology and is thoroughly detailed in the paper.

Guidelines:

- The answer NA means that the core method development in this research does not involve LLMs as any important, original, or non-standard components.
- Please refer to our LLM policy (<https://neurips.cc/Conferences/2025/LLM>) for what should or should not be described.